Phase II trial of depsipeptide (NSC-630176) in colorectal cancer patients who have received either one or two prior chemotherapy regimens for metastatic or locally advanced, unresectable disease: A Southwest Oncology Group study.

被引：0
|
作者：
Whitehead, R. P.
Mccoy, S.
Wollner, I. S.
Wong, L.
Harker, W. G.
Hoff, P. M.
Gold, P. J.
Billingsley, K. G.
Blanke, C. D.
机构：
[1] Univ Texas, Med Branch, Galveston, TX 77555 USA
[2] SW Oncol Grp, Ctr Stat, Seattle, WA USA
[3] Henry Ford Hosp, Detroit, MI 48202 USA
[4] White CCOP, Temple, TX USA
[5] Utah Canc Specialists, Salt Lake City, UT USA
[6] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Swedish Canc Inst, Seattle, WA USA
[8] Oregon Hlth Sci Univ, Inst Canc, Portland, OR 97201 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3598
引用
收藏
页码：170S / 170S
页数：1
相关论文
共 50 条
  • [41] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
    Chan, Emily
    Kwak, Eunice L.
    Hwang, Jimmy
    Heiskala, Marja
    de La Bourdonnaye, Guillaume
    Mita, Monica
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (04) : 701 - 709
  • [42] Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease
    Emily Chan
    Eunice L. Kwak
    Jimmy Hwang
    Marja Heiskala
    Guillaume de La Bourdonnaye
    Monica Mita
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 701 - 709
  • [43] Phase I/II Trial of a COX-2 Inhibitor With Limited Field Radiation for Intermediate Prognosis Patients Who Have Locally Advanced Non-Small-Cell Lung Cancer: Radiation Therapy Oncology Group 0213
    Gore, Elizabeth
    Bae, Kyounghwa
    Langer, Corey
    Extermann, Martine
    Movsas, Benjamin
    Okunieff, Paul
    Videtic, Gregory
    Choy, Hak
    CLINICAL LUNG CANCER, 2011, 12 (02) : 125 - 130
  • [44] Phase Ell, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum-based chemotherapy (INTEREST)
    Douillard, J. Y.
    Kim, E. S.
    Hirsh, V.
    Mok, T.
    Socinski, M.
    Gervais, R.
    Wu, L. Y.
    Li, L.
    Sellers, M.
    Lowe, E.
    EJC SUPPLEMENTS, 2007, 5 (06): : 2 - 2
  • [45] Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy
    Shah, Amishi Yogesh
    Gao, Jianjun
    Rezazadeh, Arash
    Cole, Suzanne
    Jain, Rohit K.
    Stevenson, Alex
    Fyvie, Gayle
    Gaw, Nina Jane
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [46] PHASE 2, OPEN-LABEL, INTERNATIONAL, NON-COMPARATIVE STUDY OF MEDI4736 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, PD-L1+, STAGE 3B-4 NSCLC WHO HAVE RECEIVED ≥2 PRIOR SYSTEMIC TREATMENT REGIMENS (ATLANTIC)
    Gray, J. E.
    Garassino, M. C.
    Vansteenkiste, J. F.
    Ballas, M.
    Jayawardene, D.
    Stockman, P. K.
    Powderly, J. D.
    Rizvi, N.
    ANNALS OF ONCOLOGY, 2015, 26
  • [47] A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: A trial of the eastern cooperative oncology group (E1500)
    Pandya, Kishan J.
    Dahlberg, Suzanne
    Hidalgo, Manuel
    Cohen, Roger B.
    Lee, Martin W.
    Schiller, Joan H.
    Johnson, David H.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (11) : 1036 - 1041
  • [48] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Jaafar Bennouna
    Istvan Lang
    Manuel Valladares-Ayerbes
    Katalin Boer
    Antoine Adenis
    Pilar Escudero
    Tae-You Kim
    Gillian M. Pover
    Clive D. Morris
    Jean-Yves Douillard
    Investigational New Drugs, 2011, 29 : 1021 - 1028
  • [49] A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
    Bennouna, Jaafar
    Lang, Istvan
    Valladares-Ayerbes, Manuel
    Boer, Katalin
    Adenis, Antoine
    Escudero, Pilar
    Kim, Tae-You
    Pover, Gillian M.
    Morris, Clive D.
    Douillard, Jean-Yves
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1021 - 1028
  • [50] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy
    Zhou, Qing
    Chen, Ming
    Wu, Gang
    Chang, Jian-Hua
    Jiang, Ou
    Cui, Jiu-Wei
    Han, Guang
    Lin, Qin
    Fang, Jian
    Chen, Gong-Yan
    Wu, Yi-Long
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (05) : 2008 - 2015
12345